technology

Our asset: a unique and proven technology platform

We use our highly innovative technology platform “Themaxyn™” to develop promising vaccines in the emerging and travelers’ vaccines market segment. Key advantages of the technology include ease of manufacture, low cost of goods, and high levels of immunogenicity. Additionally, the proven safety and efficacy profile of the parent vaccine, which the Themaxyn™ technology is based upon, suggests high probability of success and wide applicability for this vaccine platform.

Themis utilizes a highly novel vaccine vector system to create new vaccines. The Themaxyn™ vector can be loaded with antigens from a wide variety of infectious and non-infectious targets, and is based on an approved and well-known measles virus vaccine. The Themaxyn™ technology was licensed by Themis from Institut Pasteur, the Paris based world leading vaccine research institute. It encompasses a fully patent-protected, unique approach to the efficient, cost-effective and reliable manufacture of novel vaccines.

Live attenuated RNA virus vaccines are known to be very safe and effective. One or two immunizations induce life long immunity, and they can be produced at low costs. The presence of these important characteristics led to the development of the Themaxyn™ platform, which can carry difficult-to-present vaccination antigens as ‘transgenes’. Themaxyn™ can be used to express very stable transgenes, due to the small sized genome of the underlying measles virus. For the same reason, overwhelming immune responses to the vector as opposed to the transgenes are avoided, making it an ideal immunization platform since the immune response is focused on the target antigen.

Vaccines based on the Themaxyn™ platform will deliver their cargo of antigens directly to macrophages and dendritic cells - the most potent and effective antigen-presenting cells. This results in a powerful, antigen-focused immune response, which is most likely to confer immunity to the target organism.

Experimental proof-of-concept has been obtained for the Themaxyn™ system in multiple animal models across a range of indications. Importantly, it has been demonstrated that immunization with a Themaxyn-WNV (West Nile Virus) construct confers 100% protection in a mouse West Nile Virus model.

Successful experiments have also been performed in other animal models across different species, including macaques. It has been demonstrated that pre-exposure to the measles vaccine does not prevent immunity being conferred using a Themaxyn™-based vaccine construct, in both macaque and mouse HIV models.

For more detailed information on our technology plattform please do not hesitate to contact us. We are looking forward to provide you with additional information.